Morgan Stanley raised the firm’s price target on Kymera Therapeutics to $45 from $34 and keeps an Equal Weight rating on the shares. Kymera’s recent update highlighted strong pipeline progress, particularly for the I&I pipeline, and the firm awaits oncology updates by year-end and key I&I inflection points in 2025, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $38 from $30 at Wells Fargo
- Kymera Therapeutics price target raised to $60 from $46 at H.C. Wainwright
- Kymera Therapeutics reports Q2 EPS (58c), consensus (68c)
- Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7